The goal of this series is to inform jurisdictions considering whether a mobile treatment program would work in their communities and to determine what type of model would fit best.  The two mobile models featured in this article are an induction-only program that prescribes Suboxone (buprenorphine/naloxone) and a methadone delivery program that was created because of the COVID-19 public health emergency.